Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease [Phase 2]
Phase 2 clinical trial updating efficacy and safety of SCM-CGH in patients with chronic graft-versus-host disease that is steroid-refractory…
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT [Phase 3]
Phase 3 clinical trial evaluating efficacy and safety of umbilical cord-derived mesenchymal stem cells for steroid-resistant acute graft-ver…
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial evaluating atorvastatin as prophylaxis for graft-versus-host disease in allogeneic hematopoietic cell transplantation has comp…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders [Phase 2]
Phase 2 clinical trial update on donor peripheral stem cell transplantation for patients with advanced hematologic cancers and related disor…
-
CLINICAL_TRIALS trial_result · 2023-04-14Clinical Trial Update: Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation [Phase 3]
Phase 3 trial evaluating vedolizumab for prevention of intestinal acute graft-versus-host disease in patients undergoing allogeneic hematopo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Intestinal Microbiome-based Research for the Prevention of Acute GVHD [Phase 2]
Phase 2 clinical trial investigating intestinal microbiome-based approaches (postbiotics/butyrate) to prevent acute graft-versus-host diseas…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT [Phase 2, Phase 3]
Phase 2/Phase 3 trial assessing CD45RA-depleted T-cell infusion to prevent infections after TCRab/CD19-depleted allogeneic hematopoietic ste…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating tacrolimus/methotrexate with tocilizumab to prevent acute graft-versus-host disease after allogeneic hematopoietic …
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation [Phase 1, Phase 2]
Phase 1/2 trial evaluating MLN9708 (ixazomib) for prophylaxis of chronic graft-versus-host disease in patients undergoing allogeneic hematop…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects [Phase 1, Phase 2]
Pediatric phase 1/2 trial evaluating itacitinib in combination with corticosteroids for acute graft-versus-host disease; the study was termi…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. [Phase 2]
A Phase 2 single-arm trial evaluating prophylactic tocilizumab to prevent acute graft-versus-host disease after haploidentical hematopoietic…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation [Phase 3]
Phase 3 trial comparing ruxolitinib to best available therapy for corticosteroid-refractory acute graft-versus-host disease after allogeneic…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of ProTmune for allogeneic hematopoietic cell transplantation in adults with hematologic malignancies completed; results pos…
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: Itacitinib for Low Risk GVHD [Phase 2]
Phase 2 clinical trial update for itacitinib in low-risk acute GVHD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-03Clinical Trial Update: A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) [Phase 3]
Phase 3 study results for the BTK inhibitor ibrutinib in chronic graft-versus-host disease have been posted following completion of the tria…
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: Multiple Donor Treg DLI for Severe Refractory Chronic GVHD [Phase 1, Phase 2]
Phase 1/2 trial evaluating multiple donor regulatory T cell (Treg) donor lymphocyte infusion for severe refractory chronic graft-versus-host…
-
FDA approval · 2023-01-19FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) submitted by BeOne Medicines USA, Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating clofarabine, melphalan, and thiotepa followed by donor stem cell transplant for high-risk hematologic …
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan [Phase 2]
Phase II trial evaluating allogeneic hematopoietic cell transplantation for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine, and melp…
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: Abatacept s.c. for aGVHD Prevention in Haplo-HCT [Phase 1, Phase 2]
Clinical trial updates for Abatacept subcutaneous formulation in preventing acute graft-versus-host disease after haploidentical hematopoiet…
-
FDA approval · 2022-12-19FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
FDA approved a supplemental application for Jakafi (ruxolitinib) submitted by Incyte Corporation, resulting in an expanded/updated label und…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]
Phase 3 trial evaluating Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute graft-versus-host disease after myeloablative HSCT; study…
-
CLINICAL_TRIALS trial_result · 2022-10-21Clinical Trial Update: Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease [Phase 2]
Phase 2 multicenter trial evaluating natalizumab in combination with standard steroids for high-risk acute graft-versus-host disease; trial …
-
CLINICAL_TRIALS trial_result · 2022-10-13Clinical Trial Update: Clinical Trial With MSC for Graft Versus Host Disease Treatment [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating mesenchymal stem cells for the treatment of acute graft-versus-host disease has completed.
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.